External validation of the Dat'AIDS score : A risk score for predicting 5-year overall mortality in people living with HIV aged 60 years or older
© 2023 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association..
OBJECTIVE: To perform an external validation of the Dat'AIDS score for predicting 5-year overall mortality among people with HIV (PWH) aged 60 years or older.
METHODS: This was a multi-centre prospective cohort study at all sites participating in the Swiss HIV Cohort Study (SHCS). We calculated the Dat'AIDS score in PWH aged 60 years or older at their first visit between 1 January 2015 and 1 January 2020. People living with HIV-2 and those whose Dat'AIDS score could not be calculated were excluded. Patients were followed until 1 January 2020. The primary endpoint was all-cause mortality. Vital status was collected throughout the study period. We obtained population and score descriptive statistics and assessed the score's discrimination and calibration.
RESULTS: We included 2205 participants (82% male) of median [interquartile range (IQR)] age 62.0 (60.3-67.0) years, mostly with viraemia <50 copies/mL (92.7%). Median follow-up time was 15.9 years and median (IQR) CD4 cell count at enrolment was 586 (420-782) cells/μL. In all, 152 deaths were recorded during a total follow-up period of 7147 patient-years. The median (IQR) observed Dat'AIDS score was 3 (0-8). Discriminative capacities were good as the C-statistic was 0.73 (95% CI: 0.69-0.77) and consistent across all subgroups. Comparison of observed and expected survival probabilities showed good calibration.
CONCLUSIONS: External validation of the Dat'AIDS score in patients aged 60 years or older showed that it could be a useful tool not only for research purposes, but also to identify older patients at a higher mortality risk and to tailor the most appropriate interventions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
HIV medicine - 25(2024), 1 vom: 01. Jan., Seite 72-82 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hentzien, Maxime [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cohort studies |
|---|
| Anmerkungen: |
Date Completed 03.01.2024 Date Revised 03.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/hiv.13534 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361179022 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361179022 | ||
| 003 | DE-627 | ||
| 005 | 20240108141210.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/hiv.13534 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1247.xml |
| 035 | |a (DE-627)NLM361179022 | ||
| 035 | |a (NLM)37619609 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hentzien, Maxime |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a External validation of the Dat'AIDS score |b A risk score for predicting 5-year overall mortality in people living with HIV aged 60 years or older |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2024 | ||
| 500 | |a Date Revised 03.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. | ||
| 520 | |a OBJECTIVE: To perform an external validation of the Dat'AIDS score for predicting 5-year overall mortality among people with HIV (PWH) aged 60 years or older | ||
| 520 | |a METHODS: This was a multi-centre prospective cohort study at all sites participating in the Swiss HIV Cohort Study (SHCS). We calculated the Dat'AIDS score in PWH aged 60 years or older at their first visit between 1 January 2015 and 1 January 2020. People living with HIV-2 and those whose Dat'AIDS score could not be calculated were excluded. Patients were followed until 1 January 2020. The primary endpoint was all-cause mortality. Vital status was collected throughout the study period. We obtained population and score descriptive statistics and assessed the score's discrimination and calibration | ||
| 520 | |a RESULTS: We included 2205 participants (82% male) of median [interquartile range (IQR)] age 62.0 (60.3-67.0) years, mostly with viraemia <50 copies/mL (92.7%). Median follow-up time was 15.9 years and median (IQR) CD4 cell count at enrolment was 586 (420-782) cells/μL. In all, 152 deaths were recorded during a total follow-up period of 7147 patient-years. The median (IQR) observed Dat'AIDS score was 3 (0-8). Discriminative capacities were good as the C-statistic was 0.73 (95% CI: 0.69-0.77) and consistent across all subgroups. Comparison of observed and expected survival probabilities showed good calibration | ||
| 520 | |a CONCLUSIONS: External validation of the Dat'AIDS score in patients aged 60 years or older showed that it could be a useful tool not only for research purposes, but also to identify older patients at a higher mortality risk and to tailor the most appropriate interventions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HIV infections/mortality | |
| 650 | 4 | |a cohort studies | |
| 650 | 4 | |a comorbidity | |
| 650 | 4 | |a risk score | |
| 650 | 4 | |a validation study | |
| 700 | 1 | |a Frossard, Jaromil |e verfasserin |4 aut | |
| 700 | 1 | |a Kouyos, Roger |e verfasserin |4 aut | |
| 700 | 1 | |a Prendki, Virginie |e verfasserin |4 aut | |
| 700 | 1 | |a Damas, José |e verfasserin |4 aut | |
| 700 | 1 | |a Hofmann, Eveline |e verfasserin |4 aut | |
| 700 | 1 | |a Braun, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Schmid, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Bernasconi, Enos |e verfasserin |4 aut | |
| 700 | 1 | |a Ragozzino, Silvio |e verfasserin |4 aut | |
| 700 | 1 | |a Efthimiou, Orestis |e verfasserin |4 aut | |
| 700 | 1 | |a Delpierre, Cyrille |e verfasserin |4 aut | |
| 700 | 1 | |a Allavena, Clotilde |e verfasserin |4 aut | |
| 700 | 1 | |a Bani-Sadr, Firouzé |e verfasserin |4 aut | |
| 700 | 1 | |a Calmy, Alexandra |e verfasserin |4 aut | |
| 700 | 0 | |a Swiss HIV Cohort Study |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HIV medicine |d 1999 |g 25(2024), 1 vom: 01. Jan., Seite 72-82 |w (DE-627)NLM116282541 |x 1468-1293 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:1 |g day:01 |g month:01 |g pages:72-82 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/hiv.13534 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 1 |b 01 |c 01 |h 72-82 | ||